Note: This document contains side effect information about nadolol. Some of the dosage forms listed on this page may not apply to the brand name Corgard.
Applies to nadolol: oral tablet
Oral route (Tablet)
Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. The dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored when discontinuing chronic therapy, particularly in patients with ischemic heart disease. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice.
Along with its needed effects, nadolol (the active ingredient contained in Corgard) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nadolol:
Some side effects of nadolol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to nadolol: compounding powder, oral tablet
The most common adverse reactions were bradycardia, cardiac failure, rhythm/conduction disturbances, symptoms of peripheral vascular insufficiency, hypotension, dizziness, and fatigue.
Common (1% to 10%): Heart rate less than 60 beats per minute (bpm), heart rate less than 40 bpm, cardiac failure, rhythm/conduction disturbances, symptoms of peripheral vascular insufficiency usually of the Raynaud type, hypotension
Frequency not reported: First degree and third degree heart block, cold extremities
Common (1% to 10%): Dizziness
Uncommon (0.1% to 1%): Paresthesias, sedation, headache, slurred speech, tinnitus
Frequency not reported: Lightheadedness
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, bloating, flatulence, dry mouth
Uncommon (0.1% to 1%): Rash, pruritus, dry skin, sweating, facial swelling
Frequency not reported: Reversible alopecia
Uncommon (0.1% to 1%): Cough, nasal stuffiness, bronchospasm
Uncommon (0.1% to 1%): Anorexia, weight gain
Frequency not reported: Hypoglycemia
Uncommon (0.1% to 1%): Dry eyes, blurred vision
Uncommon (0.1% to 1%): Change in behavior
Frequency not reported: Insomnia
Uncommon (0.1% to 1%): Impotence or decreased libido
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Corgard